Diagnostic Approach to Sacral Wounds with Suspicious Features

Critical Diagnostic Considerations

• The National Comprehensive Cancer Network recommends immediate rebiopsy with deep tissue sampling to rule out dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation in sacral wounds with dermal fibrosis and CD34 negativity 1, 2
• CD34 negativity in a fibrotic sacral wound is highly concerning for fibrosarcomatous DFSP (FS-DFSP), which is characterized by loss of CD34 immunostaining, higher cellularity, cytologic atypia, and mitotic activity >5/10 high-power fields 1, 2
• Standard DFSP typically shows positive CD34 staining in 90% of cases, making CD34 negativity an atypical finding that warrants aggressive diagnostic workup 1, 3

Differential Diagnosis Framework

• The National Comprehensive Cancer Network suggests considering fibrosarcomatous DFSP, cutaneous squamous cell carcinoma, and other soft tissue sarcomas in the differential diagnosis of sacral wounds with suspicious features 1, 2, 4

Management Algorithm Pending Definitive Diagnosis

• The National Comprehensive Cancer Network recommends irrigating the wound with sterile saline, applying a non-adherent dressing, and changing dressings every 5-7 days unless signs of infection develop 4, 7
• Monitoring for clinical signs of infection, such as increased pain, erythema, purulent exudate, odor, wound dehiscence, or systemic signs, is crucial 4, 6

If DFSP is Confirmed

• The National Comprehensive Cancer Network suggests Mohs micrographic surgery or complete circumferential peripheral deep-margin assessment (CCPDMA/PDEMA) as the preferred surgical approach for DFSP 2, 3
• Wide excision with 2-4 cm margins extending to investing fascia, with complete histologic margin verification, is recommended when Mohs/PDEMA is unavailable 2, 3

If Fibrosarcomatous Transformation Confirmed

• The National Comprehensive Cancer Network recommends immediate multidisciplinary consultation with a sarcoma team and referral to NCCN Soft Tissue Sarcoma Guidelines for multimodal therapy 2
• FS-DFSP requires more aggressive surveillance due to higher metastasis risk 2

Follow-Up Protocol

• The National Comprehensive Cancer Network suggests clinical examination of the primary site every 6-12 months for a minimum of 5 years after treatment, with rebiopsy of any suspicious areas immediately during surveillance 2, 3